首页> 外文期刊>Biological & pharmaceutical bulletin >Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models.
【24h】

Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models.

机译:YM358(一种血管紧张素II 1型(AT1)受体拮抗剂)和依那普利对两种肾性高血压模型的血压和血管收缩的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The effects of the angiotensin II type 1 receptor antagonist YM358 on blood pressure were compared to those of the angiotensin converting enzyme inhibitor enalapril in one-kidney, one-clip renal hypertensive rats (1K1C RHR), two-kidney, one-clip renal hypertensive rats (2K1C RHR) and normotensive rats (NTR). Additionally, the local drug actions in peripheral tissues were investigated using isolated mesenteric arteries from these rats. In 2K1C RHR, YM358 and enalapril produced a long-lasting hypotensive effect in a dose-dependent manner. In 1K1C RHR, YM358 (30 mg/kg) also produced an antihypertensive effect, whereas enalapril (30 mg/kg) had no effect. Administration of YM358, but not enalapril, to 1K1C RHR, 2K1C RHR and NTR did not affect heart rate. In isolated mesenteric arteries from 1K1C RHR and 2K1C RHR, angiotensin II (Ang II), angiotensin I (Ang I) and tetradecapeptide (TDP), a physiologically active renin substrate, produced concentration-dependent vasoconstriction. YM358 (10(-7) M) inhibited the vasoconstricting responses to Ang II, Ang I and TDP in isolated mesenteric arteries. In contrast, enalaprilat (10(-7) M), an active metabolite of enalapril, did not completely inhibit the response to Ang I and TDP. These results indicate that YM358 has higher efficacy than enalapril for the treatment of hypertension.
机译:将一肾一夹肾型高血压大鼠(1K1C RHR),二肾一夹肾型高血压大鼠中血管紧张素II 1型受体拮抗剂YM358与血管紧张素转化酶抑制剂依那普利的血压作了比较大鼠(2K1C RHR)和血压正常大鼠(NTR)。另外,使用从这些大鼠分离的肠系膜动脉研究了外周组织中的局部药物作用。在2K1C RHR中,YM358和依那普利以剂量依赖性方式产生了持久的降压作用。在1K1C RHR中,YM358(30 mg / kg)也产生抗高血压作用,而依那普利(30 mg / kg)则无作用。对1K1C RHR,2K1C RHR和NTR施用YM358,而不是依那普利,不影响心率。在从1K1C RHR和2K1C RHR分离的肠系膜动脉中,血管紧张素II(Ang II),血管紧张素I(Ang I)和四肽(TDP)(一种具有生理活性的肾素底物)产生了浓度依赖性的血管收缩。 YM358(10(-7)M)在孤立的肠系膜动脉中抑制对Ang II,Ang I和TDP的血管收缩反应。相反,依那普利(10(-7)M)是依那普利的活性代谢产物,并未完全抑制对Ang I和TDP的反应。这些结果表明,YM358在高血压方面比依那普利具有更高的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号